Universal Biosensors H1 2024 Investor Presentation

Universal Biosensors H1 2024 investor presentation highlights 19% sales growth and improved gross margins year-over-year. Key performance drivers include 73% growth in Xprecia sales and 76% revenue growth in HRL, though Sentia sales declined 8%. The company reported improving profitability with positive underlying NPAT and expanding margins across the portfolio.